Amsterdam-based Royal Philips announces that it has formed a strategic collaboration with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to integrate its BioSticker medical device into Philips’ remote patient monitoring (RPM) offering to help monitor at-risk patients from the hospital into the home. With the addition of multi-parameter sensors, Philips’ solutions can enhance how clinicians monitor patient populations living with chronic conditions in their homes with passive monitoring of key vital signs, physiological biometrics and symptomatic events via a wearable patch for monitoring up to 30 days.
“Building on Philips’ global leadership in patient monitoring, which includes an extensive suite of advanced monitoring solutions, platforms and sensors, this is the latest example of our capability to allow more seamless, cloud-based data collection across multiple settings from the home to the hospital and back into the home,” says Roy Jakobs, chief business leader connected care, member of the executive committee at Royal Philips. “Patient data, coupled with our clinically differentiated and leading AI-powered technology, quantifies the data into relevant actionable insights to help detect deterioration trends and support care interventions—all while outside the walls of the hospital.”
Wireless, Secure Data Transfer of Key Vital Signs
The BioSticker is a single-use, FDA-cleared 510k class II wearable medical device to enable at-home continuous passive monitoring with minute level data across a broad set of vital signs, physiological biometrics, and symptomatic events (skin temperature, resting heart rate, resting respiratory rate, body position, activity levels, cough frequency) on a single device for 30 days.
Symptoms, including those directly associated with COVID-19 such as temperature and respiratory rate, can be remotely monitored in confirmed cases of coronavirus and also for those patients not sick enough to be hospitalized, or those suspected of having COVID-19. In addition to COVID-19, the BioSticker device will help transform the way clinicians monitor and manage patients living with chronic conditions from the home.
“Multi-parameter sensors are the natural next phase for remote monitoring, especially at a time when more patients are engaging with their physicians from home,” said James Mault, MD, founder and CEO of BioIntelliSense. “Clinicians need medical-grade monitoring and algorithmic clinical insights for COVID-19 exposure, symptoms and management.
“Philips is a demonstrated leader in remote patient monitoring, and we look forward to BioIntelliSense’s technology playing an integral role in simplifying and enhancing outcomes for patients and their doctors,” Mault adds.